UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
January 28, 2002
----------------
(Date of Report)
ENTROPIN, INC.
--------------
(Exact name of registrant as specified in its charter)
Colorado 33-23693 84-1090424
- ---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
45926 Oasis Street, Indio, California 92201
-------------------------------------------
(Address of principal executive offices, including zip code)
(760) 775-8333
--------------
(Registrant's telephone number, including area code)
N/A
----
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS.
- ---------------------
Entropin, Inc. ("Entropin") issued the following press release on
January 24, 2002:
ENTROPIN NAMES DENNIS K. METZLER TO BOARD OF DIRECTORS
INDIO, Calif. (JANUARY 24, 2002) - Entropin, Inc. (Nasdaq: ETOP; ETOPW) is
a specialty pharmaceutical company developing new therapeutics for painful
soft tissue injuries and diseases. Today, the Company announced the
appointment of Dennis K. Metzler, 61, to the Entropin Board of Directors,
bringing the total number of Directors to eight.
Mr. Metzler is an attorney and entrepreneur with over 30 years of business
experience. He is currently President of Metzler Enterprises, Inc., based
in Fresno, California, and is involved in real estate development and
various investment activities. Previously Mr. Metzler was Chief Executive
Officer and co-owner of his family's diversified and integrated farming
business, H.P. Metzler & Sons, based in Fresno, California. Earlier, Mr.
Metzler practiced law in Los Angeles for twelve years with the law firm of
Shutan and Trost (now Sidley, Austin, Brown & Wood). He received his J.D.
from University of Southern California Law School.
While CEO of H. P. Metzler & Sons, the world's largest grower of Granny
Smith apples, Mr. Metzler served on several industry boards, including the
Produce Marketing Association. Additionally, he has previously served as
a board member for numerous organizations, including the Fresno Economic
Development Corporation, the Fresno Metropolitan Museum, the Boy Scouts of
America and St. Agnes Medical Center. Mr. Metzler is currently serving as
Chairman of The Fellowship of Christian Athletes, Chairman of A Place For
You Foundation, and is an active member of the World President's
Organization.
"Dennis is a valuable addition to our Board of Directors," said Higgins D.
Bailey, Ed.D., Entropin's Chairman. "His legal background, varied general
business experience, and network of financial contacts will be particularly
helpful."
Dr. Bailey continued, "Dennis' appointment completes our Board. We now have
Directors with in-depth experience in the key areas of drug development and
corporate business. I believe Dennis will be a major contributor to the
future success of Entropin."
Commenting on his Board appointment, Mr. Metzler said, "I am looking
forward to joining Entropin's outstanding Board and serving as a Director.
Esterom(R) is a unique product and I am enthusiastic about its potential to
help people and contribute to the future success of the Company."
2
ABOUT ENTROPIN
Entropin, Inc. is a pharmaceutical research and development company,
initially focused on the development of Esterom(R), a novel topical
therapeutic for the treatment of painful soft tissue injuries, such as
tendonitis or back sprain, that result in impaired function.
THIS NEWS RELEASE INCLUDES FORWARD-LOOKING STATEMENTS THAT REFLECT
ENTROPIN'S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND FINANCIAL
PERFORMANCE. THE WORDS "BELIEVE," "EXPECT," "ANTICIPATE," AND SIMILAR
EXPRESSIONS IDENTIFY FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING
STATEMENTS ARE SUBJECT TO A VARIETY OF RISKS, UNCERTAINTIES, AND OTHER
FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE
EXPRESSED IN ANY SUCH FORWARD-LOOKING STATEMENTS. THESE FACTORS INCLUDE,
BUT ARE NOT LIMITED TO: (1) THE ABILITY TO SUCCESSFULLY COMPLETE
DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS, INCLUDING THE COST, SCOPE
AND RESULTS OF PRE-CLINICAL AND CLINICAL TESTING; (2) THE ABILITY TO
SUCCESSFULLY COMPLETE PRODUCT RESEARCH AND FURTHER DEVELOPMENT, INCLUDING
PRE-CLINICAL AND CLINICAL STUDIES; (3) THE TIME, COST AND UNCERTAINTY OF
OBTAINING REGULATORY APPROVALS; (4) THE ABILITY TO OBTAIN SUBSTANTIAL
ADDITIONAL FUNDING; (5) THE ABILITY TO DEVELOP AND COMMERCIALIZE PRODUCTS
BEFORE COMPETITORS; AND (6) OTHER FACTORS DETAILED FROM TIME TO TIME IN
FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION.
# # #
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: January 28, 2002 ENTROPIN, INC
By: /s/ THOMAS G. TACHOVSKY
--------------------------------
Thomas G. Tachovsky
President and Chief Executive Officer
3